Fig. 2

mRNA overexpression of LANCL2 and EGFR was common in GBM specimens of TCGA database, but was not associated with prognosis of GBM patients. A, B mRNA expression levels of LANCL2 and EGFR in 32 different cancers of TCGA Pan-Cancer Atlas database. C Frequencies of LANCL2 and EGFR mRNA overexpression in two TCGA studies of GBM and LGG. D Frequencies of LANCL2 and EGFR mRNA overexpression in different pathological types of gliomas. E, F The correlations between CNVs and mRNA expression of LANCL2 or EGFR in GBM. P values were determined by Kruskal–Wallis One-Way ANOVA and Dunn’s multiple comparisons. ***p < 0.001. G Frequencies of concurrent mRNA overexpression of LANCL2 and EGFR in total or EGFR-overexpressed GBM samples. H A significant association between the mRNA expression levels of LANCL2 and EGFR in GBM. I Forest plot showing the univariate analysis for OS according to the mRNA expression of LANCL2 and EGFR in GBM patients of TCGA database. P values and hazard ratios were determined by log-rank test